{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=U.S.+Army+Medical+Research+and+Development+Command",
    "query": {
      "sponsor": "U.S. Army Medical Research and Development Command",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 237,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=U.S.+Army+Medical+Research+and+Development+Command&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=U.S.+Army+Medical+Research+and+Development+Command&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T11:40:05.396Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01360736",
      "title": "A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2 (SAFEMIL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Suicide",
        "Suicide, Attempted"
      ],
      "interventions": [
        {
          "name": "Safety Planning - Military (SAFE MIL)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 102,
      "start_date": "2009-09",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01360736"
    },
    {
      "nct_id": "NCT01517711",
      "title": "Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post-Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Tramadol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2022-08-31",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01517711"
    },
    {
      "nct_id": "NCT02689713",
      "title": "Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Thermal Injury",
        "Burns",
        "Hyperalgesia"
      ],
      "interventions": [
        {
          "name": "Voriconazole (topical)",
          "type": "DRUG"
        },
        {
          "name": "Topical Sterile Water Placebo Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kenneth Hargreaves",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-15",
      "completion_date": "2018-11-14",
      "has_results": false,
      "last_update_posted_date": "2018-12-17",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02689713"
    },
    {
      "nct_id": "NCT01540474",
      "title": "Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Group 1: 10 ug FMP012 with 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Group 2: 10 ug FMP012 with 5 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Controlled group-Challenged Only: no vaccination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-02",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540474"
    },
    {
      "nct_id": "NCT02733614",
      "title": "Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "SRX246",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azevan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2016-12",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02733614"
    },
    {
      "nct_id": "NCT04302766",
      "title": "Expanded Access Remdesivir (RDV; GS-5734™)",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 14,
      "location_summary": "San Diego, California • Jacksonville, Florida • Fort Benning, Georgia + 11 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Fort Benning",
          "state": "Georgia"
        },
        {
          "city": "Fort Gordon",
          "state": "Georgia"
        },
        {
          "city": "Tripler AMC",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04302766"
    },
    {
      "nct_id": "NCT01554891",
      "title": "INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Injuries, Traumatic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 305,
      "start_date": "2012-02",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Augusta, Maine • Manchester, New Hampshire + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Maine"
        },
        {
          "city": "Manchester",
          "state": "New Hampshire"
        },
        {
          "city": "White River Junction",
          "state": "Vermont"
        },
        {
          "city": "Fort Belvoir",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01554891"
    },
    {
      "nct_id": "NCT02386150",
      "title": "ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ - 3-Dose Primary Series With Boost",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ricin Poisoning"
      ],
      "interventions": [
        {
          "name": "RVEc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-10",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02386150"
    },
    {
      "nct_id": "NCT00657618",
      "title": "Use of Sodium Stibogluconate as a Treatment for Leishmaniasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leishmaniasis"
      ],
      "interventions": [
        {
          "name": "Sodium Stibogluconate (SSG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 77,
      "start_date": "2004-10",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657618"
    },
    {
      "nct_id": "NCT01968590",
      "title": "Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "25 Years to 40 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-16",
      "completion_date": "2022-01-01",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-10-11T11:40:05.396Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968590"
    }
  ]
}